
The study examines the impact of modulator therapy access on anxiety and depression in cystic fibrosis (CF) patients and their caregivers. Group 1 (pre-ETI treatment) had lower depression and anxiety levels compared to Groups 2 and 3 (limited access). Access to modulator therapy reduced anxiety by 67.7%. The study highlights the importance of addressing access barriers to improve mental health outcomes for CF patients and caregivers.
Like
Save
Share